Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

  • End date
    Oct 31, 2021
  • participants needed
  • sponsor
    Tufts Medical Center
Updated on 26 August 2020


The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A total of approximately 18 subjects will take part in the dose escalation part of the study and an additional 25 subjects will participate in the expansion cohort. This study will be conducted across four centers in the United States.


The primary objective of this study is to assess the safety and toxicity of a fractionated docetaxel schedule in combination with standard Ra-223.

Secondary Objectives include: assessment of progression-free survival, time to treatment failure, overall survival, ability of subjects to complete 6 cycles of the combination therapy, assessment of Prostate Specific Antigen (PSA) kinetics and objective responses (measurable disease), assessment of quality of life and assessment of bone bio-marker outcomes.

The study features a 4-week lead-in period with docetaxel monotherapy to assess for docetaxel intolerance. The lead-in period is then followed by combination therapy with Ra-223 every 4 weeks for 6 cycles in a traditional Phase I dose-escalation design.

A provision has been made to include prophylactic granulocyte colony stimulating factor (G-CSF) cohorts after the lead-in period if neutropenia is the dose limiting toxicity at either dose level.

The investigators hypothesize that the fractionated dosing of docetaxel will significantly mitigate the hematologic toxicity, preserve antineoplastic activity and allow for maintenance of the 4-weekly Ra-223 schedule.

Treatment docetaxel, Radium 223
Clinical Study IdentifierNCT03737370
SponsorTufts Medical Center
Last Modified on26 August 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Metastatic Castrate Resistant Prostate Cancer?
Histologically or cytologically confirmed adenocarcinoma of the prostate
Documented metastatic castration resistant disease with PSA progression, radiographic progression, or both, despite medical or surgical castration
Two or more bone metastases detected on skeletal scintigraphy
Eligible for docetaxel chemotherapy
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Adequate organ function
Hemoglobin > 10 g/dL
Absolute Neutrophil Count > 1,500 K/mL
Platelet count > 150,000 x 10^9/L
Total bilirubin < 1.5x upper limit of normal range, excluding Gilbert syndrome
Serum aspartate aminotransferase (AST) < 1.5 x upper limit of normal range
Serum alanine aminotransferase (ALT) < 1.5 x upper limit of normal range
Estimated glomerular filtration rate (GFR) > 30mL/min
Age 18 years
Ongoing castration (androgen deprivation therapy or prior orchiectomy)
Male subjects with female sexual partners of childbearing potential must agree to use at least one highly effective methods of birth control
Ability to understand and willingness to sign an informed consent form prior to initiation of any study procedures

Exclusion Criteria

Prior radionuclide therapy for CRPC
Prior docetaxel for CRPC. (Permitted if given for castration sensitive disease > 6 months prior)
Antiandrogen therapy within 4 weeks of enrollment. However, patients with primary failure of secondary anti-androgen therapy OR symptomatic progression, objective progression and/or biochemical evidence of rising PSA less than 4 weeks after discontinuation of anti-androgen therapy will not have anti-androgen withdrawal responses and will not be excluded
Preexisting peripheral neuropathy grade 2 or higher
Other serious medical condition as judged by the investigator
Active second malignancy that requires therapy
Known brain or leptomeningeal metastases
Concurrent enrollment in any other investigational anticancer therapy
Treatment with any myelosuppressive agent within 30 days of enrollment
Presence of bulky visceral metastases, defined as any of the following
lung lesions (at least 1cm each in size in the longest diameter) or pulmonary lymphangitic metastasis
Liver metastases with sum of lesion diameters totaling 5cm
Evidence of neuroendocrine or small cell differentiation on prior biopsy
History of severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet